fbpx Improving Detection of Neurotoxicity in Immunotherapies - Challenge | JLABS
image

Improving Detection of Neurotoxicity in Immunotherapies

52 days remaining

Grant funding up to increments of $200,000, $125,000, and $75,000

Overview

There are new immunotherapy cancer treatments available for hematologic malignancies, such as T-cell based immunotherapies and chimeric antigen receptor T-cell (CAR-T) therapies. However, some patients experience neurotoxicity as a result of treatment. Clinical symptoms or signs can be progressive and may include aphasia, altered level of consciousness, impairment of cognitive skills, motor weakness, seizures, and cerebral edema.

Although sometimes severe, neurotoxicity is primarily reversible and can be detected through specialized patient monitoring and care. Early detection of acute toxicities may enable earlier intervention and ultimately result in improved outcomes for patients. For example, research suggests that analyzing patients’ handwriting may aid in identifying neurotoxicity prior to the presentation of other noticeable symptoms.

To inspire early identification of neurotoxicity, Johnson & Johnson Innovation, together with Janssen Global Services, is proud to launch the Improving Detection of Neurotoxicity in Immunotherapies QuickFire Challenge. Visionaries are invited to submit methods and technologies aiming to optimize patient care for immunotherapies within the hematologic malignancy space by enabling early detection of neurotoxic events. Of particular interest are technologies aiming to identify clinical manifestations to predict acute toxicities, including movement and neurocognitive disorders.

The innovator(s) with the best potential solution can receive grant funding in increments up to $200,000, $125,000, or $75,000, access to the global Johnson & Johnson Innovation – JLABS network and mentorship from experts at the Johnson & Johnson Family of Companies (‘Johnson & Johnson’).*

* Subject to the execution of the necessary documentation and (award) agreements.

Why this challenge matters to us

At Johnson & Johnson Innovation, Our Credo inspires us to put the needs and well-being of the people we serve first. Working together, we can spark the next great idea that can potentially change the trajectory of health for patients around the world.

What we’re looking for

Visionaries are invited to submit methods and technologies aiming to optimize patient care for immunotherapies within the hematologic malignancy space by enabling early detection of neurotoxic events. Of particular interest are technologies aiming to identify clinical manifestations to predict acute toxicities, including movement and neurocognitive disorders.

Criteria

Potential solutions will be evaluated by an independent panel of reviewers and judges on their ability to meet the following criteria:

  • Accuracy in detecting and characterizing clinical manifestations, with a specific interest in variations in handwriting including micrographia, dysgraphia, and agraphia
  • Patient accessibility
  • Seamlessly integrates into healthcare settings and existing patient care model
  • Feasibility and plans for deployment
  • Potential impact

Awards

  • Grant funding up to increments of $200,000, $125,000, and $75,000
  • Access to the global Johnson & Johnson Innovation - JLABS (‘JLABS’) network
  • Mentorship from experts across the Johnson & Johnson Family of Companies (‘Johnson & Johnson’)*

FAQs

What if I’m having trouble accessing the portal/website?

 Make sure your browser is up to date and accepting cookies. You can contact customer service at [email protected] if you are having technical difficulties as well.

 Can I submit supporting documents (for example a video) as part of my application?

You will have the opportunity and are encouraged to upload supporting materials such as non-confidential slide decks, research papers, and videos as part of your application. You may submit a video along with your typed responses. Maximum length is 2 minutes. Make sure that you do not submit any information that is non-proprietary or owned by a third party.

Is it ok if some of the information I submit is confidential?

Do not submit confidential information. Only non-confidential information should be submitted and anything you submit will be treated as non-confidential.

What happens with IP (Intellectual Property)?

As this is a no strings attached arrangement, JLABS does not acquire any IP.  Any IP creation and/or protection remains the sole responsibility of the inventors.

Is a patent required to apply?

No, a patent is not required to apply.  However, you should not submit any information that you wish to keep confidential or that may negatively impact the future patentability of your invention, or that is considered a trade secret or privileged.

What kind of science / technology is appropriate for the Challenges?

We encourage all to apply. Find out more about what areas we desire to explore here: https://www.jnjinnovation.com/partnering

Who is eligible to apply?

Each Challenge has its own terms & conditions that we require you to accept, and that can be found prior to filling out the application.

Which stage of innovation are you interested in?

We are interested in tangible innovations at a variety of stages – including ideation, prototyping, piloting, and commercial launches. Submissions should align to our areas of focus and not be limited to academic research projects.

What are the specific criteria for application?

Potential solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:

 

  • Accuracy in detecting and characterizing clinical manifestations, with a specific interest in variations in handwriting including micrographia, dysgraphia, and agraphia
  • Patient accessibility
  • Seamlessly integrates into healthcare settings and existing patient care model
  • Feasibility and plans for deployment
  • Potential impact

Who can I contact if I have questions about the Challenge or the application process?

Please contact [email protected] with any questions.

Where do I apply? And do I have to complete the application in one sitting?

You can setup an account at https://jnj-quickfire.smapply.io. You are able to save your work and log back in to finish at a later time if needed.

What types of ideas are you interested in?

Submissions should have path to commercialization. While ideas can be early-stage, we are not looking for research projects not pursuing a viable potential solution.

Timeline

December 1, 2021
Launch
March 18, 2022
Deadline
2022
Announcement

About the Janssen Pharmaceutical Companies of Johnson & Johnson

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

About Johnson & Johnson Innovation

Johnson & Johnson Innovation LLC works across the pharmaceutical, medical device and consumer health sectors to accelerate early-stage, transformational solutions by catalyzing the best ideas, wherever they are in the world. We do this by harnessing our deep scientific capabilities coupled with a wide range of tools, including customized deal structures, company creation, incubation and startup services, capital investments and other innovative business models that aim to meet the diverse needs of entrepreneurs, scientists and emerging companies. Our goal is to help life science and health technology innovations thrive through collaboration and partnership with the global ecosystem, so that together we can change the trajectory of human health. Meet our passionate team of science and technology experts and learn how to collaborate with us at www.jnjinnovation.com.